Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide plus low-dose dexamethasone in relapsed/refractory multiple myeloma
CTR20230801Phase 3Active
- Sponsor
- Changzhou Pharmaceutical Factory
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pomalidomide, dexamethasone in multiple myeloma (MM), sponsored by Changzhou Pharmaceutical Factory. Started Nov 2024; status: active.
02
Drugs
pomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20230801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230801.